Recursion Pharmaceuticals, Inc. (RXRX) Tops Q4 EPS by 4c

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) reported Q4 EPS of ($0.42), $0.04 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $10.89 million versus the consensus estimate of $19.9 million.

For earnings history and earnings-related data on Recursion Pharmaceuticals, Inc. (RXRX) click here.

You May Also Be Interested In

• Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
• Sunbelt Rentals Holdings, Inc. (SUNB) Reports Q2 EPS of $1.18
• J.Jill (JILL) Tops Q2 EPS by 67c, Beats on Revenue; Offers Guidance